The COVID-19 outbreak and resulting restrictions have created several challenges for clinical trial programmes by pharmaceutical companies.
GlobalData has conducted a survey to identify how companies are addressing the disruptions amid the pandemic.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Findings of the survey reveal that a majority 17% of the companies have turned to remote monitoring of the patients and are using portals, phones and email for oversight.
Addressing clinical trial disruptions due to COVID-19 outbreak
Decentralised/virtual clinical trials are being planned for future programmes by approximately 15% of the respondents, while 14% are adopting remote site initiation visits for critical trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, 13% of the surveyed companies mandated their research staff to work remotely, while 11% have resorted to direct-to-patient (DTP) drug delivery.
The survey also found that 9% of the respondents suspended screening and/or enrolment for all clinical trials, while 7% prioritised enrolment for certain trial programmes and another 7% implemented remote safety lab collections.
Additionally, 7% of the total companies surveyed have stopped opening any new clinical trial programmes due to the pandemic situation.
The analysis is based on responses received from the COVID-19 Pandemic Impact on Clinical Trials survey conducted by GlobalData between 04 June and 22 June 2020.
